Miguel T. Hernandez

Santa Cruz De Tenerife, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Prognostic value of interim PET-CT in follicular lymphoma.

Prognostic value of interim PET-CT in follicular lymphoma.

Journal: Medicina clinica

Published: September 24, 2025

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.

Journal: HemaSphere

Published: December 20, 2024

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 22, 2024

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 22, 2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Journal: Haematologica

Published: April 23, 2024

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience.

High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience.

Journal: HemaSphere

Published: March 07, 2024

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Journal: Blood cancer journal

Published: November 09, 2023

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.

Journal: Haematologica

Published: September 20, 2023

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.

Journal: Frontiers in oncology

Published: March 30, 2023

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Journal: Blood

Published: December 28, 2022

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Journal: Haematologica

Published: November 29, 2022

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Journal: Nature communications

Published: November 25, 2022

Showing 1-12 of 54

Last Updated: 09/26/2026